[Management of side effects of everolimus treatment for metastatic renal cell carcinoma].
Hinyokika Kiyo. 2012 Nov;58(11):647-50
Authors: Mikami K, Hongo F, Miki T
Abstract
Treatment with everolimus is known to prolong progression-free survival in patients with renal cell carcinoma resistant against tyrosine-kinase inhibitor therapy. The side effects must be known for more effective use of this drug. Information of side effects was collected from a randomized controlled study, the early post-marketing phase vigilance and from our own experience. Interstitial lung disease (ILD) was a potentially severe side effect. Incidence of ILD was relatively large compared with that of other target therapy agents. Infections, thrombocytopenia, stomatitis and others were experienced as other side effects. However, there were few uncontrollable side effects. Management of side effects of everolimus can be improved by obtaining sufficient knowledge.
PMID: 23254794 [PubMed - in process]
没有评论:
发表评论